

Is a 'Cancer Check-Up' Near for High-Risk Adults? Clinician Attitudes and Perspectives on Multi-Cancer Early Detection (MCED) Tests

Tariqa Ackbarali, PhD¹, Catherine R. Marinac, PhD², Tomasz M. Beer, MD, FACP³

1 - PlatformQ Health, LLC, Needham, MA;

2 - Dana-Farber Cancer Institute, Boston, MA;

3 - Oregon Health & Science University, Portland, OR

This activity is supported by an educational grant from GRAIL Inc.

INTRODUCTION AND METHODOLOGY

Educational Gaps and Program Details



Current cancer screening guidelines are limited, covering only 5 tumor types



Despite the potential of MCED tests, these are not yet FDA approved and are viewed with both enthusiasm and hesitation



To address the gaps in the education around MCED tests and evaluate clinician perceptions, two educational initiatives were developed in 2020 and 2021



Two Activities Over the Course of 2020 and 2021



Partners

Education: PlatformQ Health, PIM



Measurements

Questions asked pre-, immediate post-, and 2-months post-activity. Chi Square tests used for statistical analysis



Interventions

Two 60-min CME activities for HCPs.

September 2020: “Taking Steps Toward Achieving Cancer Control: Is Multi-Cancer Screening the Solution?”

July 2021: “The Cancer Check-Up: Early Detection Using Multi-Cancer Screening”

The 2020 activity introduced the value proposition and trial designs of MCED tests and reviewed the current cancer screening guidelines. **Challenges revealed from the 2020 activity informed the multidisciplinary approach of the 2021 activity presenting epidemiology, oncology, and primary care perspectives.**

FACULTY



Minetta C. Liu, MD

Professor and Research Chair,
Department of Oncology,
Mayo Clinic



Catherine R. Marinac, PhD

Assistant Professor of Medicine
Dana-Farber Cancer Institute



Andrew Hudnut, MD

Family Medicine Specialist
Vice President of Elk Grove
Sutter Medical Group Division



Tomasz M. Beer, MD, FACP

Professor of Medicine, Deputy Director
Grover C. Bagby Endowed Chair for Prostate
Cancer Research;
Deputy Director, OHSU Knight Cancer Institute;
Chief Medical Officer, CEDAR
Professor of Medicine, Hematology &
Medical Oncology;
Director, Prostate Cancer Research Program
Oregon Health & Science University

RESULTS

Learner Demographics



total learners



MD/NP/PA



average years
in practice



target audience
learners*



identified
themselves as
treaters



average patient
visits weekly

Learner Engagement



certificates
awarded



slides
downloaded




average time in
session



learner
questions

*Target Audience: Primary care physicians, internists, family physicians, oncologists, nurses, physician assistants and nurse practitioners in primary care practices.

Impact on Clinical Practice



n=88

of learners reported the activities positively impacted their clinical practice



134

write-in examples were shared

Better able to assess the therapeutic potential of multi-cancer screening tests to transform cancer care


The knowledge that this liquid-based testing is available for early screening and its positive outcome

Better communication with patients, including informed shared decision-making!

Increasing population awareness towards regular checking up for early detection of cancer with positive impact on both prognosis and survival

RESULTS

Impact on Patient Experiences/Outcomes



n=85

of learners reported the activities positively impacted their patients' experiences or outcomes

Earlier detection and impact on improving survival

More prepared to transfer eligible patients to cancer screening center


I inform the patients of the availability of this new screening tool and the efficacy of the liquid-based testing

I recommended screening tests for my patients

RESULTS


Changes in Knowledge/Competence

Recognition of the value of MCED testing




n = 4,711 pretest, n = 2,934 posttest

Competence selecting appropriate screening modalities (e.g. liquid biopsy)



n = 1,059 pretest, n = 671 posttest

Competence counseling patients on current recommended screening




n = 1,059 pretest, n = 671 posttest

RESULTS


Changes in Knowledge/Competence

Knowledge of and competence counseling patients on MCED test specificity




n = 3,652 pretest, n = 2,263 posttest

Competence with clinical workflow after signal detected from MCED test



n = 3,652 pretest, n = 2,263 posttest


Competence with clinical workflow after signal not detected from MCED test



n = 3,652 pretest, n = 2,263 posttest


RESULTS

Recognition of Benefits of MCED Tests in Practice




RESULTS

Likelihood of Integrating MCED Tests in Practice




RESULTS

Identification of Patients Most Likely to Benefit from an MCED Test



RESULTS

Barriers to Utilizing Multi-Cancer Early Detection Tests in Practice



2020 n = 1,625

2021 n = 3,593



Learn More About the Impact of Emerging Diagnostics:



These data provide real-world insight into clinician perspectives on MCED tests and the clinical, patient-care, and workflow challenges that should be considered before incorporating future approaches on multi-cancer screening. As the primary care setting is most suited for the introduction of novel cancer-screening tools, PCPs and oncologists will require continued education to apply practical strategies for point-of-care decision-making and transitions-of-care protocols.